<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04599075</url>
  </required_header>
  <id_info>
    <org_study_id>H00021746</org_study_id>
    <nct_id>NCT04599075</nct_id>
  </id_info>
  <brief_title>Intravenous Insulin vs Subcutaneous Insulin Infusion in Intrapartum Management of Type 1 Diabetes Mellitus</brief_title>
  <official_title>Intravenous Insulin Versus Subcutaneous Insulin Infusion in Intrapartum Management of Pregnant Women With Type 1 Diabetes Mellitus: A Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gianna Wilkie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Massachusetts, Worcester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to perform a randomized trial to investigate if intrapartum&#xD;
      insulin delivery mechanisms reduces adverse outcomes associated with type 1 diabetes in&#xD;
      pregnancy. The investigators aim to compare subcutaneous insulin pump versus intravenous&#xD;
      insulin infusion with regard to the primary outcome of neonatal blood sugar.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intrapartum glucose management is critical to reducing neonatal hypoglycemia shortly after&#xD;
      birth. Some providers are comfortable continuing patients on their subcutaneous insulin pump&#xD;
      during labor while others transition these patients to intravenous insulin infusions.&#xD;
      Previous literature has retrospectively shown this to be both a feasible and safe option.&#xD;
&#xD;
      The investigators aim to compare subcutaneous insulin pump versus intravenous insulin&#xD;
      infusion with regard to obstetric and neonatal outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a prospective, single-center, randomized study evaluating intrapartum insulin delivery management strategies among pregnant women with type 1 diabetes mellitus.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Those assessing the outcomes from the medical chart will be blinded to the randomization process and the assigned study arm. Patients, the primary investigator, and their care providers will be aware of their treatment status.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Neonatal Hypoglycemia</measure>
    <time_frame>Within 2 hours of birth</time_frame>
    <description>First neonatal blood sugar obtained within 2 hours of birth</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of maternal intrapartum glucose measurements</measure>
    <time_frame>During Labor</time_frame>
    <description>Number of maternal intrapartum glucose measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal glucose values</measure>
    <time_frame>During labor</time_frame>
    <description>Each maternal glucose values obtained during labor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of maternal hypoglycemic events</measure>
    <time_frame>During labor</time_frame>
    <description>Number of maternal blood sugars &lt; 60 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Diabetic Ketoacidosis during labor</measure>
    <time_frame>During Labor</time_frame>
    <description>Development of Diabetic Ketoacidosis during labor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mode of Delivery</measure>
    <time_frame>At birth</time_frame>
    <description>Mode of Delivery (vaginal versus cesarean)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Birthweight</measure>
    <time_frame>At Birth</time_frame>
    <description>Neonatal Birthweight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with shoulder dystocia</measure>
    <time_frame>At birth</time_frame>
    <description>Number of participants with shoulder dystocia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with brachial plexus injury</measure>
    <time_frame>At birth</time_frame>
    <description>Number of participants with brachial plexus injury</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apgar Score</measure>
    <time_frame>At delivery</time_frame>
    <description>Neonatal Apgar Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal mean glucose level</measure>
    <time_frame>Within 24 hours of life</time_frame>
    <description>Neonatal mean glucose level in first 24 hours of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Received neonatal intervention for hypoglycemia</measure>
    <time_frame>Within 24 hours of life</time_frame>
    <description>Received intervention for hypoglycemia (any oral, IV, or both)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Intensive Care Unit Admission</measure>
    <time_frame>At delivery and within first 2 day of life</time_frame>
    <description>Admission to level 2 or greater neonatal ICU and length of stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Intensive Care Unit Admission for hypoglycemia</measure>
    <time_frame>At delivery and within first 2 day of life</time_frame>
    <description>Admission to level 2 or greater neonatal ICU for hypoglycemia and length of stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gestational age at delivery</measure>
    <time_frame>At birth</time_frame>
    <description>Gestational age at delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with neonatal respiratory distress</measure>
    <time_frame>At delivery</time_frame>
    <description>Requiring 2 or more hours of respiratory support or oxygen with associated diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with neonatal hyperbilirubinemia</measure>
    <time_frame>Within first 2 days of life</time_frame>
    <description>Requiring phototherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from birth to first neonatal glucose measurement</measure>
    <time_frame>Within first 3 hours of life</time_frame>
    <description>Time from birth to first neonatal glucose measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal Care Satisfaction Survey</measure>
    <time_frame>Postpartum, assessed within 4 days of delivery</time_frame>
    <description>Survey assessing satisfaction with healthcare provided</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placental Pathology</measure>
    <time_frame>At birth</time_frame>
    <description>Assessing for malperfusion pathology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Umbilical Cord Blood Level of C-peptide</measure>
    <time_frame>At Birth</time_frame>
    <description>Umbilical Cord Blood Level of C-peptide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Umbilical Cord Blood Level of Leptin</measure>
    <time_frame>At Birth</time_frame>
    <description>Umbilical Cord Blood Level of Leptin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Umbilical Cord Blood Level of Insulin</measure>
    <time_frame>At Birth</time_frame>
    <description>Umbilical Cord Blood Level of Insulin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Type 1 Diabetes</condition>
  <condition>Pregnancy, High Risk</condition>
  <arm_group>
    <arm_group_label>Intravenous Insulin Infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be randomized to discontinuation of the CSII pump intrapartum and initiation of IV insulin infusion per hospital protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuous Subcutaneous Insulin Infusion (CSII)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be randomized to continuation of their CSII pump intrapartum and will be managed in accordance with the CSII hospital protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>IV Insulin Infusion</description>
    <arm_group_label>Intravenous Insulin Infusion</arm_group_label>
    <other_name>Insulin via IV Infusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>Continuous Subcutaneous Insulin Infusion (Pump)</description>
    <arm_group_label>Continuous Subcutaneous Insulin Infusion (CSII)</arm_group_label>
    <other_name>Insulin via Pump</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant women with pre-gestational diagnosis of type 1 diabetes mellitus and managed&#xD;
             on an insulin pump in pregnancy&#xD;
&#xD;
          -  Pregnancy and delivery care obtained at University of Massachusetts (UMass) Memorial&#xD;
             Medical Center&#xD;
&#xD;
          -  Patients able to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are under the age of 18&#xD;
&#xD;
          -  Patients with altered state of consciousness&#xD;
&#xD;
          -  Critically ill patient requiring intensive care unit admission&#xD;
&#xD;
          -  Patient at risk for suicide&#xD;
&#xD;
          -  Patient refuses or is otherwise unable to participate in own care&#xD;
&#xD;
          -  Patient without pump supplies&#xD;
&#xD;
          -  Patients presenting with diabetic ketoacidosis on admission&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gianna L Wilkie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMass Memorial Health Care</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gianna L Wilkie, MD</last_name>
    <phone>508-334-4067</phone>
    <email>Gianna.Wilkie@umassmemorial.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Heidi Leftwich, DO</last_name>
    <email>Heidi.Leftwich@umassmemorial.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Massachusetts Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianna L Wilkie, MD</last_name>
      <phone>508-334-4067</phone>
      <email>Gianna.Wilkie@umassmemorial.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Feldberg D, Dicker D, Samuel N, Peleg D, Karp M, Goldman JA. Intrapartum management of insulin-dependent diabetes mellitus (IDDM) gestants. A comparative study of constant intravenous insulin infusion and continuous subcutaneous insulin infusion pump (CSIIP). Acta Obstet Gynecol Scand. 1988;67(4):333-8.</citation>
    <PMID>3051881</PMID>
  </reference>
  <reference>
    <citation>Peterson C, Grosse SD, Li R, Sharma AJ, Razzaghi H, Herman WH, Gilboa SM. Preventable health and cost burden of adverse birth outcomes associated with pregestational diabetes in the United States. Am J Obstet Gynecol. 2015 Jan;212(1):74.e1-9. doi: 10.1016/j.ajog.2014.09.009. Epub 2014 Oct 28.</citation>
    <PMID>25439811</PMID>
  </reference>
  <reference>
    <citation>Professional Practice Committee for the Standards of Medical Care in Diabetes-2016. Diabetes Care. 2016 Jan;39 Suppl 1:S107-8. doi: 10.2337/dc16-S018.</citation>
    <PMID>26696673</PMID>
  </reference>
  <reference>
    <citation>Drever E, Tomlinson G, Bai AD, Feig DS. Insulin pump use compared with intravenous insulin during labour and delivery: the INSPIRED observational cohort study. Diabet Med. 2016 Sep;33(9):1253-9. doi: 10.1111/dme.13106. Epub 2016 Mar 20.</citation>
    <PMID>26927202</PMID>
  </reference>
  <reference>
    <citation>Fresa R, Visalli N, Di Blasi V, Cavallaro V, Ansaldi E, Trifoglio O, Abbruzzese S, Bongiovanni M, Agrusta M, Napoli A. Experiences of continuous subcutaneous insulin infusion in pregnant women with type 1 diabetes during delivery from four Italian centers: a retrospective observational study. Diabetes Technol Ther. 2013 Apr;15(4):328-34. doi: 10.1089/dia.2012.0260. Epub 2013 Mar 28.</citation>
    <PMID>23537417</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 16, 2020</study_first_submitted>
  <study_first_submitted_qc>October 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Massachusetts, Worcester</investigator_affiliation>
    <investigator_full_name>Gianna Wilkie</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Pregnancy</keyword>
  <keyword>Type 1 Diabetes</keyword>
  <keyword>Intrapartum Insulin</keyword>
  <keyword>Maternal Outcomes</keyword>
  <keyword>Neonatal Outcomes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

